Rhinovirus C represents a group within the Picornaviridae family distinguished from the more widely studied Rhinovirus A and B types. Despite being identified only in recent decades, RV-C has been strongly correlated with more severe lower respiratory tract infections, especially in children, immunocompromised individuals, and those with asthma. The absence of a reliable cell culture system that supports robust RV-C replication has long hindered efforts to understand its pathobiology and hampers antiviral development. Previous models have either failed to sustain infection or lacked the physiological relevance required for meaningful translational research.

The novel infection system introduced by Lyoo and colleagues circumvents these limitations through a meticulously engineered cellular environment. Their approach integrates differentiated human airway epithelial cells cultured under air-liquid interface conditions, which recapitulate the human respiratory epithelium’s multicellular complexity. Crucially, the model supports full viral entry, replication, and release, mimicking natural infection dynamics more closely than any prior in vitro system. This breakthrough enables researchers to dissect the viral lifecycle at unprecedented resolution.

From a technical perspective, the model exploits human primary airway basal cells that, over several weeks, differentiate into ciliated, goblet, and club cells. These cell types collectively form an intact mucociliary epithelium responsible for barrier defense and mucosal immunity. The investigators also optimized culture conditions, including specific growth factors and extracellular matrix components, to enhance cellular differentiation and maintain epithelial polarity. Such physiological fidelity is critical because RV-C selectively targets ciliated cells, a feature often lost in standard monolayer cultures.

The team employed a panel of clinical RV-C isolates to validate their system, demonstrating consistent viral replication kinetics and cytopathic effects aligned with in vivo observations. Importantly, viral RNA quantification via RT-qPCR and immunofluorescence staining for viral capsid proteins confirmed productive infection over multiple replication cycles. This comprehensive confirmation allows for detailed mechanistic studies of RV-C-host interactions, including receptor usage, immune evasion, and pathogenicity factors that were previously inaccessible.

In addition to basic virology, the infection model is positioned as a high-throughput platform for antiviral screening. Using well-established antiviral compounds and novel chemical libraries, the researchers performed dose-response assays that revealed potent inhibitors capable of blocking RV-C replication without compromising epithelial integrity. This proof of concept opens avenues for targeted drug design and repurposing existing therapeutics, significantly shortening the timeline from discovery to clinical application.

The implications of this research extend beyond mere model development. RSV, influenza, and common cold viruses have historically benefited from advanced culture systems that facilitated vaccine and drug development, yet RV-C lagged behind due to technical obstacles. The methodology pioneered here thus narrows this gap, allowing direct comparative studies of Rhinovirus subtypes under unified experimental conditions, improving the epidemiological and clinical understanding of respiratory viral infections.

Moreover, the model’s physiological accuracy provides an excellent framework for studying host immune responses to RV-C. The differentiated epithelial cells secrete cytokines and interferons upon infection, which can be quantitatively measured and manipulated using genetic or pharmacological tools. This will help delineate pathways integral to viral pathogenesis and immune modulation, ultimately informing host-targeted therapies or immune-boosting agents tailored to vulnerable patient populations.

One of the most pressing questions in RV-C research concerns its distinctive receptor profile, primarily the cadherin-related family member 3 (CDHR3), which had eluded functional characterization due to lack of suitable in vitro systems. The new model permits targeted modulation of CDHR3 expression and the exploration of viral binding specificity and entry mechanisms under native cellular contexts. These studies might reveal novel antiviral targets and clarify the genetic risk factors associated with severe RV-C infections observed in certain human populations.

The cell-based infection framework is also adaptable to co-infection studies, evaluating the interplay between RV-C and other respiratory pathogens such as bacteria or fungi. Understanding these interactions is vital given the frequent polymicrobial nature of respiratory illnesses that complicate diagnosis and treatment. With this system, researchers can dissect the synergistic or antagonistic effects on host tissues and uncover potential vulnerabilities that combination therapies could exploit.

Further extending its utility, the model enables the examination of environmental and physiological variables on RV-C infection, including the impact of temperature gradients, hypoxia, and exposure to pollutants. These factors are crucial in mimicking the respiratory tract’s microenvironment and reflect real-world conditions influencing viral transmission and severity. Insight gained here could guide public health interventions and inform personalized medicine approaches for respiratory infection management.

This innovative study also fosters new opportunities for vaccine development against RV-C. By enabling the propagation of viral particles in a controlled but biologically authentic system, it provides a stable platform for producing vaccine antigens and testing immunogenicity. Such translational potential is critical as no vaccine currently exists for any Rhinovirus species, despite their massive global health burden.

In summary, the establishment of a robust human airway epithelium cell-based infection model marks a significant milestone in Rhinovirus C research. It addresses a longstanding void in the field by allowing detailed viral lifecycle studies, antiviral drug screening, and host-pathogen interaction analyses under physiologically relevant conditions. This work not only propels fundamental virology but also holds promise for practical applications in disease prevention and treatment.

As respiratory viruses continue to challenge global health systems, advancements like this exemplify the power of combining cellular engineering with virology to uncover new frontiers. The research led by Lyoo et al. represents a beacon for scientists and clinicians dedicated to combating viral respiratory diseases through innovative, translational science.

Ongoing studies are anticipated to refine and expand this model, potentially incorporating immune cells and three-dimensional organoid technologies to capture further complexity of human airway biology. Such enhancements will deepen understanding of RV-C pathogenesis and ultimately contribute to more effective therapeutics and vaccines, heralding a new era in respiratory virology research.

The full article detailing these findings and methodological specifics can be accessed in the forthcoming 2026 issue of npj Viruses, providing a valuable resource for the global virology and infectious disease research community.

Subject of Research: Development of a human airway epithelial cell-based infection model for Rhinovirus C to facilitate virological studies and antiviral drug discovery.

Article Title: A robust cell-based infection model for Rhinovirus C research and antiviral drug discovery.

Article References:
Lyoo, H., Alpizar, Y.A., Sablon, C. et al. A robust cell-based infection model for Rhinovirus C research and antiviral drug discovery. npj Viruses (2026). https://doi.org/10.1038/s44298-026-00194-5

Image Credits: AI Generated

Dr. Max A. Seibold, PhD, director of the Regenerative Medicine and Genome Editing Program at National Jewish Health, spearheaded the research team that embarked on this in-depth analysis of early-life viral infections. Their study distinguishes itself by examining the independent and combinatorial effects of multiple viral pathogens on the risk of developing severe lower respiratory disease, a critical factor influencing both immediate infant health and potential long-term respiratory conditions such as asthma.

The research reveals that not all viruses affect the lower respiratory tract uniformly. Respiratory syncytial virus (RSV), a well-recognized pathogen, was confirmed as the predominant agent linked to severe lower respiratory illness in infants. Infants infected with RSV showed nearly a ninefold increase in the likelihood of developing serious respiratory complications. Complementary viruses such as metapneumovirus, parainfluenza viruses, and certain endemic coronaviruses were also associated with elevated risks but to lesser extents compared to RSV.

In contrast to these high-risk viruses, rhinovirus and bocavirus, despite being the most commonly detected pathogens in both mild and severe cases, displayed a unique pattern. Individually, these viruses often caused mild upper respiratory infections analogous to the common cold. However, the study uncovered that when these two viruses co-infect an infant simultaneously, the risk for a severe lower respiratory tract infection substantially increases, nearly tripling the odds relative to single-virus infections. This synergy suggests complex viral-viral interactions that may potentiate pathogenicity through mechanisms still to be fully elucidated.

Interestingly, SARS-CoV-2, the pandemic coronavirus, manifested unexpected dynamics in this young cohort. Unlike its severe respiratory impact in adults, SARS-CoV-2 infections in infants correlated with a comparatively lower risk of progressing to severe disease. This phenomenon supports emerging evidence that infants’ innate and adaptive immune responses differ markedly from adults, potentially conferring protective effects against severe COVID-19 manifestations during early development.

The study leveraged extensive metagenomic sequencing and epidemiologic surveillance, enabling researchers to map precise viral profiles and their temporal dynamics within the nasopharynx and lower airways. This high-resolution approach allowed for disentangling the independent contributions of each viral species and their co-infection frameworks. Such detailed characterization is critical in understanding how viral ecology shapes disease severity and progression in infancy.

National Jewish Health researchers emphasize that the results have significant clinical implications. Identifying high-risk viruses and viral combinations can guide preventative strategies, including timely vaccination protocols and heightened clinical surveillance for infants exhibiting co-infections. Tailored approaches could mitigate the burden of severe respiratory diseases during this vulnerable developmental window and potentially reduce the incidence of chronic respiratory disorders later in life.

Furthermore, these findings underscore the importance of comprehensive viral monitoring, particularly in populations such as Puerto Rican infants who experience disproportionately elevated rates of asthma and respiratory morbidities. By elucidating the viral determinants of illness severity, healthcare providers can better allocate resources and interventions towards groups most at risk.

The study also sets a foundation for future research into host-pathogen interactions, exploring how viral pathogenic mechanisms and host immune responses coalesce to dictate health outcomes. Unraveling these complex interactions offers promise for novel therapeutic targets and precision medicine interventions aimed at mitigating viral respiratory disease severity.

National Jewish Health remains at the forefront of respiratory health research, integrating cutting-edge molecular techniques with clinical expertise to pioneer advances in understanding and treating respiratory illnesses across the lifespan. As respiratory viruses continue to evolve and challenge public health, studies like this provide essential knowledge to adapt and improve preventive and therapeutic measures for young children worldwide.

Continued vigilance and investment in virologic and immunologic research are paramount, especially in the context of global respiratory pathogens whose impacts extend far beyond infancy. The insights gleaned from this study illuminate pathways to protect the youngest and often most vulnerable members of the population, ensuring healthier respiratory futures.

Subject of Research: The independent and interactive impacts of multiple viral species on the severity of early-life lower respiratory tract illnesses in infants.

Article Title: Independent and interactive effects of viral species on early-life lower respiratory tract illness

News Publication Date: 20-Oct-2025

Web References:
10.1016/j.jinf.2025.106616 (DOI link)

Keywords: Epidemiology, Health care, Human health, Virology, Respiratory infections, Infant health, Lower respiratory tract illness, Viral co-infection, RSV, Rhinovirus, Bocavirus, SARS-CoV-2